Candel Therapeutics has secured a much-needed win for its herpes simplex-based immunotherapy, CAN-2409. Phase III results show it helped improve disease-free survival for men with localized prostate cancer, with the readout coming in the nick of time in terms of the company’s finances.
Candel’s Phase III Prostate Cancer Win Comes In the Nick Of Time
The biotech’s lead candidate now looks approvable as the first new localized prostate cancer treatment in 20 years – allowing Candel to raise much-needed funds – but a filing must wait
